Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2010

Iris Pays BioMicro Systems $3.2M for Instrument that Automates FISH Testing

  • Iris acquired the assets of a multipurpose, bench-top instrument for automating highly repetitive, manual laboratory protocols for FISH testing and other slide-based cytogenetic applications. The product and proprietary technology assets were purchased for $3.2 million in cash from BioMicro Systems.

    The system has been developed as a standalone instrument capable of automating a growing number of laboratory protocols. It is user programmable and is capable of automating most steps of the FISH test protocol with a reduction in technology labor and an increase in reliability, according to the Iris.

    The initial and primary market focus for the instrument will be for FISH applications, although, the system also automates other processes for WISH (whole mount in-situ hybridization), immunohistochemistry, Western/Southern/Northern blots, and other slide-based applications.

    "The protocols used for FISH testing are very time- and temperature-sensitive and can take up to eight hours of hands-on processing time," says Robert Mello, president of the Iris sample processing division. "Through independent laboratory evaluations, we found the system was able to cut technologist's labor by at least 50% while avoiding potential operator errors, fulfilling a significant need in the marketplace as there is a declining number of CLIA-certified technicians."

    BioMicro's platform will be integrated into Iris' sample processing division. It is expected to boost Iris' position in the cytogenetic instrumentation market.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »